These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 31504303)
41. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Nelson DR; Cooper JN; Lalezari JP; Lawitz E; Pockros PJ; Gitlin N; Freilich BF; Younes ZH; Harlan W; Ghalib R; Oguchi G; Thuluvath PJ; Ortiz-Lasanta G; Rabinovitz M; Bernstein D; Bennett M; Hawkins T; Ravendhran N; Sheikh AM; Varunok P; Kowdley KV; Hennicken D; McPhee F; Rana K; Hughes EA; Hepatology; 2015 Apr; 61(4):1127-35. PubMed ID: 25614962 [TBL] [Abstract][Full Text] [Related]
42. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients. Jain A; Kalra BS; Srivastava S; Chawla S Indian J Gastroenterol; 2019 Feb; 38(1):39-43. PubMed ID: 30710219 [TBL] [Abstract][Full Text] [Related]
43. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. Cheng PN; Chiu YC; Chien SC; Chiu HC J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677 [TBL] [Abstract][Full Text] [Related]
44. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience. Goel A; Bhargava R; Rai P; Aggarwal R Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492 [TBL] [Abstract][Full Text] [Related]
45. Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study. Aluzaite K; Fraser M; Johnson S; Giles H; Schultz M N Z Med J; 2020 Nov; 133(1525):53-61. PubMed ID: 33223548 [TBL] [Abstract][Full Text] [Related]
46. Therapy for hepatitis C genotype 3: moving forward. Buti M; Llaneras J; Riveiro-Barciela M; Esteban R J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352 [TBL] [Abstract][Full Text] [Related]
47. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study. Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166 [TBL] [Abstract][Full Text] [Related]
48. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X; Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736 [TBL] [Abstract][Full Text] [Related]
49. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965 [TBL] [Abstract][Full Text] [Related]
50. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855 [TBL] [Abstract][Full Text] [Related]
52. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Sulkowski MS; Flamm S; Kayali Z; Lawitz EJ; Kwo P; McPhee F; Torbeyns A; Hughes EA; Swenson ES; Yin PD; Linaberry M Liver Int; 2017 Jun; 37(6):836-842. PubMed ID: 27943563 [TBL] [Abstract][Full Text] [Related]
53. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162 [TBL] [Abstract][Full Text] [Related]
54. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. Chuang WL; Chien RN; Peng CY; Chang TT; Lo GH; Sheen IS; Wang HY; Chen JJ; Yang JC; Knox SJ; Gao B; Garrison KL; Mo H; Pang PS; Hsu YC; Hu TH; Chu CJ; Kao JH J Gastroenterol Hepatol; 2016 Jul; 31(7):1323-9. PubMed ID: 26841930 [TBL] [Abstract][Full Text] [Related]
55. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan. Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554 [TBL] [Abstract][Full Text] [Related]
56. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263 [TBL] [Abstract][Full Text] [Related]
57. Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil. Ferreira VL; Borba HHL; Wiens A; Pedroso MLA; Radunz VFC; Ivantes CAP; Kuniyoshi ASO; Pontarolo R Braz J Infect Dis; 2018; 22(3):186-192. PubMed ID: 29752891 [TBL] [Abstract][Full Text] [Related]
58. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650 [TBL] [Abstract][Full Text] [Related]
59. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C. Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411 [TBL] [Abstract][Full Text] [Related]
60. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]